ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.33−0.09 (-0.79%)
Close on Nov 17, 2026Market cap $102.90MP/E 141.6Yield –
ImmuCell operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
ImmuCell's operating cash flow for the twelve months ending Jun 30, 2026 was $5.89M, up 132.6% year over year. For fiscal 2025 it was $2.48M, up 591.6% from the year before. Over ten years it grew -1.6% a year on average. The highest annual figure on record is $2.90M in fiscal 2015.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.48M | +591.6% |
| FY2024 | Dec 31, 2024 | $357.90K | – |
| FY2023 | Dec 31, 2023 | -$4.67M | – |
| FY2022 | Dec 31, 2022 | -$1.54M | -261.8% |
| FY2021 | Dec 31, 2021 | $954.17K | -27.5% |
| FY2020 | Dec 31, 2020 | $1.32M | +463.4% |
| FY2019 | Dec 31, 2019 | $233.51K | – |
| FY2018 | Dec 31, 2018 | -$373.40K | -131.8% |
| FY2017 | Dec 31, 2017 | $1.18M | – |
| FY2016 | Dec 31, 2016 | -$222.31K | -107.7% |
| FY2015 | Dec 31, 2015 | $2.90M | +859.2% |
| FY2014 | Dec 31, 2014 | $302.36K | -72.5% |
| FY2013 | Dec 31, 2013 | $1.10M | +219.0% |
| FY2012 | Dec 31, 2012 | $344.39K | – |
| FY2011 | Dec 31, 2011 | -$37.32K | – |
| FY2010 | Dec 31, 2010 | -$808.61K | – |
| FY2009 | Dec 31, 2009 | -$109.67K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.02M | +88.5% |
| Q1 FY2026 | Mar 31, 2026 | $3.57M | +127.0% |
| Q4 FY2025 | Dec 31, 2025 | $482.54K | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.18M | – |
| Q2 FY2025 | Jun 30, 2025 | $1.60M | +175.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.57M | +276.1% |
| Q4 FY2024 | Dec 31, 2024 | -$3.05K | – |
| Q3 FY2024 | Sep 30, 2024 | -$639.33K | – |
| Q2 FY2024 | Jun 30, 2024 | $581.78K | – |
| Q1 FY2024 | Mar 31, 2024 | $418.51K | – |
| Q4 FY2023 | Dec 31, 2023 | -$723.07K | – |
| Q3 FY2023 | Sep 30, 2023 | -$507.75K | – |
| Q2 FY2023 | Jun 30, 2023 | -$681.43K | -282.5% |
| Q1 FY2023 | Mar 31, 2023 | -$2.76M | -532.6% |
| Q4 FY2022 | Dec 31, 2022 | -$1.30M | -320.8% |
| Q3 FY2022 | Sep 30, 2022 | -$1.26M | -585.7% |
| Q2 FY2022 | Jun 30, 2022 | $373.46K | -48.9% |
| Q1 FY2022 | Mar 31, 2022 | $638.54K | – |
| Q4 FY2021 | Dec 31, 2021 | $587.89K | +276.3% |
| Q3 FY2021 | Sep 30, 2021 | $258.99K | – |
| Q2 FY2021 | Jun 30, 2021 | $730.83K | -24.6% |
| Q1 FY2021 | Mar 31, 2021 | -$623.55K | -172.7% |
| Q4 FY2020 | Dec 31, 2020 | $156.25K | – |
| Q3 FY2020 | Sep 30, 2020 | -$667.33K | – |
| Q2 FY2020 | Jun 30, 2020 | $969.20K | – |
| Q1 FY2020 | Mar 31, 2020 | $857.45K | +26.6% |
| Q4 FY2019 | Dec 31, 2019 | -$46.62K | – |
| Q3 FY2019 | Sep 30, 2019 | -$66.41K | – |
| Q2 FY2019 | Jun 30, 2019 | -$330.66K | -1658.3% |
| Q1 FY2019 | Mar 31, 2019 | $677.20K | +171.2% |
| Q4 FY2018 | Dec 31, 2018 | -$138.35K | -141.8% |
| Q3 FY2018 | Sep 30, 2018 | -$505.94K | – |
| Q2 FY2018 | Jun 30, 2018 | $21.22K | – |
| Q1 FY2018 | Mar 31, 2018 | $249.66K | -80.1% |
| Q4 FY2017 | Dec 31, 2017 | $330.71K | – |
| Q3 FY2017 | Sep 30, 2017 | -$255.12K | – |
| Q2 FY2017 | Jun 30, 2017 | -$155.12K | – |
| Q1 FY2017 | Mar 31, 2017 | $1.26M | – |
| Q4 FY2016 | Dec 31, 2016 | -$372.04K | – |
| Q3 FY2016 | Sep 30, 2016 | -$16.33K | – |
See a number that looks wrong?